‚P�¬’r�K�G‘¼�@�‚—îŽÒŠÌŠà‚ɑ΂·‚郉ƒWƒI”g�ĎܗÖ@�@2003�@“ú–{�¬�l•aŠw‰ï
‚Q�¬’r�K�G‘¼�@ŠÌŠàŽ¡—ÃŒã‚ÌŠÌ‹@”\�„ˆÚ�@2002�@“ú–{�Á‰»Ší•aŠw‰ï‘�‰ï
‚RKoike Y et al. Changes in Hepatic Functional Reserve after
Percutaneous Tumor Ablation for Hepatocellular Carcinoma�@2003�@•Ä�‘�Á‰»Ší•aŠw‰ï
‚SKoike
Y et al. Risk factors for recurring hepatocellular carcinoma differ according
to infected hepatitis virus-an analysis of 236 consecutive patients with a
single lesion. Hepatology 2000 Dec;32(6):1216-23
‚TShiratori
Y,et al. Interferon therapy after tumor ablation improves prognosis in patients
with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med
2003 Feb 18;138(4):299-306
